Clinical trials: Attention Deficit Disorders With Hyperactivity
ADHD
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).
- Trial name
- NCT00764868
- Testing
- Lisdexamfetamine Dimesylate (LDX)
- Where
- 45 sites in United States
- Volunteers
- 269 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
- Trial name
- NCT02083783
- Testing
- TRI102
- Where
- 5 sites in United States
- Volunteers
- 108 people
- Sponsor
- Tris Pharma, Inc.
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders
The objective of this K01 study was to pilot a sequential, multiple assignment, randomized trial (SMART) design to compare the impact of a sequence of sleep interventions, based on participant treatment response, to optimize…
- Conditions
- Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Sleep Disturbance
- Trial name
- NCT03730194
- Testing
- Melatonin, Bedtime Bank
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Nebraska
Attention Deficit Hyperactivity Disorder
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
LYDO is a multi-center study that will enroll approximately 1925 adult outpatients with Attention Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00700427
- Testing
- atomoxetine hydrochloride
- Where
- 56 sites in Austria, Belgium and 10 more
- Volunteers
- 2,017 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
- Trial name
- NCT02777931
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Autism, Attention Deficit Disorder With Hyperactivity
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD.
- Trial name
- NCT00178503
- Testing
- Methylphenidate-extended release, Methylphenidate-immediate release
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Sleep Apnea, Obstructive, Sleep Apnea Syndromes
Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children
Obstructive sleep-disordered breathing (SDB) affects 2-3% of children and may lead to problems with nighttime sleep and daytime behavior, learning, sleepiness, and mood.
- Conditions
- Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity
- Trial name
- NCT01554527
- Testing
- CPAP treatment, No CPAP treatment
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Michigan
Attention-Deficit/Hyperactivity Disorder
Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
This proposal seeks to obtain preliminary data on the potential efficacy, tolerability, and feasibility of trigeminal nerve stimulation (TNS) as a treatment for Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01388530
- Testing
- EMS 7500 Digital Muscle Stimulator
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom…
- Trial name
- NCT03649074
- Testing
- AKL-T01
- Where
- 2 sites in United States
- Volunteers
- 206 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Disorder With Hyperactivity
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
This study will determine the effectiveness of stimulant and nonstimulant medication in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents.
- Trial name
- NCT00183391
- Testing
- Atomoxetine, Methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 232 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult…
- Trial name
- NCT00636818
- Testing
- Atomoxetine
- Where
- 11 sites in China, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Adult ADHD
Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
This was a Phase 2 exploratory study to evaluate the efficacy and safety of EB-1020 SR (centanafadine sustained release [CTN SR]) in treating participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth…
- Trial name
- NCT01939353
- Testing
- CTN SR
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study
This proposed research will use randomized control trial (RCT) methodology and compare micronutrients with placebo in 135 children with ADHD.
- Trial name
- MADDY (NCT03252522)
- Testing
- Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
- Where
- 3 sites in United States, Canada
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Pervasive Development Disorders
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a…
- Trial name
- NCT01238575
- Testing
- extended-release guanfacine
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Yale University
ADHD
ADHD Treatment for Latino Families
The current pilot study aims to close the existing gap in our knowledge about effective psychosocial treatments for Latino families by providing preliminary data regarding the acceptability and efficacy of a culturally-modified…
- Trial name
- NCT02317692
- Testing
- Parent training
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Marquette University
TBI (Traumatic Brain Injury), Brain Injuries
Brain Markers of Improvements in Cognitive Functioning
Some of the most common, persistent, and disabling consequences of traumatic brain injury affect an individual's ability to achieve personal goals.
- Conditions
- TBI (Traumatic Brain Injury), Brain Injuries, Stress, Attention Deficit
- Trial name
- NCT03490110
- Testing
- State regulation skill training, Treatment-as-usual
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- VA Office of Research and Development
Attention Deficit Hyperactivity Disorder
Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse
This is an open label pilot study to obtain information on the best way to study young adolescents with Attention Deficit Hyperactivity Disorder (ADHD)who may also be at risk of developing substance abuse, in part because of…
- Trial name
- NCT00573534
- Testing
- Vyvanse
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
ADHD
Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
The purpose of this study is to determine the effects of Vyvanse, an FDA approved medication used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), on brain activity in adults with attention-deficit…
- Trial name
- NCT01924429
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jeffrey Newcorn
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study
The overall goal of the present project is to investigate whether lisdexamphetamine (LDX; Vyvanse) is an effective adjunct to nicotine replacement therapy (NRT) to promote smoking cessation in patients with comorbid Attention…
- Trial name
- NCT00736255
- Testing
- Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Duke University